Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

e becoming effective, Shire Limited was

substituted for Shire plc as principal obligor under Shire's $1.1

billion 2.75 per cent convertible bond due 2014 originally issued by

Shire plc (and the terms and conditions of such bonds were accordingly

amended).

- Shire incurred costs associated with the introduction of the new

holding company of $12.2 million in the six months to June 30, 2008.

Completion of acquisition of METAZYM

- On June 4, 2008 Shire completed the acquisition of the global rights to

the clinical candidate arylsulfatase-A, currently known as METAZYM,

from Zymenex for $135 million in cash (see Pipeline Highlights above).

This acquisition is expected to bring forward Shire's entry into the

MLD market.

Sale of non-core assets

- Following the transfer of the relevant marketing consents

Shire recognised previously deferred gains of $9.1 million arising from

product divestments in 2007, including $8.6 million from the sale of

non-core products to Laboratorios Almirall S.A ("Almirall") in 2007.

HGT analyst day

- Shire is planning an analyst day for November 18, 2008 in

Lexington, Massachusetts - specific details will be issued nearer the

date.

Share purchases

- In the three months to June 30, 2008 1.4 million American

Depositary Shares ("ADSs") were acquired by the Employee Share

Ownership Trust ("ESOT") for a cash consideration of $71.0 million

(2007: $55.5 million) at an average ADS price of $50.12.

Board changes

- On June 18, 2008 Shire's former Chief Financial Officer,

Angus Russell, became Chief Executive Officer and Shire's former Chief

Executive Officer Matthew Emmens became Chairman and Non-Executive

Director. Shire's former Chairman, Dr James Cavanaugh, retired from the

Shire Board and David Kappler becam
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...st people would like to be able to charge their ce...nd not too often. A recent discovery made by UC Sa...sed supercapacitors that could do just this. , ...Letters , Prabhakar Bandaru, a professor in the UC...ing, along with graduate student Mark Hoefer, have...
(Date:11/19/2009)..., BLAUVELT, N.Y., Nov. 19 Dr. M...rm extract, responds to a press release issued on ...ngarian company for making false and self-serving ...ciences. ,, Dr. Hidvegi stated from his office...m that research on Avemar does not apply to AveULT...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/...vator in biotechnology for diabetes therapy, and a...ervices to food, supplement, biotechnology and pha... of Tuesday,s Annual Meeting of Shareholders. ,...ated (Nasdaq: SPEX ) elected the following member...
(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Thera...st patient in a randomized Phase 2B study of AEG35... development for multiple oncology indications. ,...Phase 2 Study of the X-Linked Inhibitor of Apoptos...with High-dose Cytarabine and Idarubicin in AML Fo...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...artin Brand collaborate with Seahorse Bioscience, ...shop and will share their years of experience stud...ndees , , N. BILLERICA, Mass., May 29 Seahorse B...and consumables for cell based metabolic assays an...p, " Understanding When and How to Use Intact Cel...
...ully Delivered into the Bloodstream , , - Data De...evels of Oxycodone , , MELBOURNE, Australia, May ...POH; OTCQX: PPGNY) today announced the successful ...atented TPM/oxycodone transdermal patch system. Th...that by incorporating TPM/oxycodone into innovativ...
...29 Exiqon Diagnostics, announced today a strategi...innovative, comprehensive internet based solution ...eful knowledge on the latest topics in cancer trea...izing cancer care through novel molecular and cell...tory services, will become a content partner by pr...
Other Biology Technology:New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 2New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 2Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 3
(Date:11/19/2009)...end of the last ice age, North America,s vast asse...atures as mammoths, mastodons, camels, horses, gro...ous slide to extinction. , And when their popula...large animals equaled or surpassed Africa,s wildli...novel ecosystem emerged as broadleaved trees once ...
(Date:11/19/2009)...lti-institutional effort co-led by three Cold Spri...today in publication of a landmark series of paper...ted detail the DNA sequence of maize ( Zea mays ).... American consumers, is one of the world,s most im...crop grown in the United States, representing $47 ...
(Date:11/19/2009)...T. Ming Chu Professor of Biochemistry and Molecula...g how regulatory proteins control the production o...king with collaborators including Drs. Mitchell We...adelphia, they focused specifically on the complex...s). These cells contain large amounts of hemoglobi...
Breaking Biology News(10 mins):After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Hospital Corporation of America Recognized by InformationWeek as One of Nations Most Innovative Users of Business Technology 57262 1Hospital Corporation of America Recognized by InformationWeek as One of Nations Most Innovative Users of Business Technology 57262 2Weighing costs benefits of HIV treatments 57258 1Weighing costs benefits of HIV treatments 57258 2Weighing costs benefits of HIV treatments 57258 3New Web site promotes interoperable newborn screening data 9938 1New Web site promotes interoperable newborn screening data 9938 2
...2008) While pondering the challenges of distingui... mass of hundreds or thousands of nanoprobes, rese...an interesting observation. The tiny, clustered do...ear night. , The biomedical researchers realized ... solving a problem very similar to their own isol...
...e center of some of the nation,s most pressing cha... global climate change. To provide a critical over...emies are convening a summit of leading energy exp...nd the private sector. The event will inform an Ac...uture: Technology Opportunities, Risks, and Tradeo...
...ersity of York have characterised an important new...ur immune system. , It is an invisibility cloak ...zae, a common cause of ear infections in children,... attacked by the immune system. , A multidiscipl...y and Chemistry at York have been studying how bac...
Other Biology News:Astronomy technology brings nanoparticle probes into sharper focus 2Astronomy technology brings nanoparticle probes into sharper focus 3NAS to hold 2-day summit on energy issues 2
Mouse Anti-Yellow Fever Virus Monoclonal Antibody, Unconjugated, Clone 3576 from Abcam
Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Gel Loading Dye (Bromophenol Blue/Glycerol) from Mo Bio Laboratories, Inc.
Anti-JNK1 / SAPK Antibody, Unconjugated from Cell Sciences
Biology Products: